Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)

BACKGROUND: Angiogenesis has been a major target of novel drug development in hepatocellular carcinoma (HCC). It is hypothesized that the combination of two antiangiogenic agents, sorafenib and bevacizumab, will provide greater blockade of angiogenesis. OBJECTIVE: To determine the optimal dose, safe...

詳細記述

保存先:
書誌詳細
出版年:Target Oncol
主要な著者: Hubbard, Joleen M., Mahoney, Michelle R., Loui, William S., Roberts, Lewis R., Smyrk, Thomas C., Gatalica, Zoran, Borad, Mitesh, Kumar, Shaji, Alberts, Steven R.
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5586602/
https://ncbi.nlm.nih.gov/pubmed/27943153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-016-0467-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料